U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
182820 Q3 2022 ANHYDROUS LACTOSE ORAL TABLET, DELAYED RELEASE 3250mg Correction
182821 Q4 2022 ANHYDROUS LACTOSE ORAL TABLET, DELAYED RELEASE 1083mg Correction
182942 Q4 2022 ADIPIC ACID VAGINAL TABLET 57.00 mg Deletion
182943 Q4 2022 ANHYDROUS CITRIC ACID ORAL LIQUID, EXTENDED RELEASE 5.18 mg/ 1.00 ml 62mg Deletion
182944 Q4 2022 ANHYDROUS TRISODIUM CITRATE ORAL LIQUID, EXTENDED RELEASE 3.90 mg/ 1.00 ml 47mg Deletion
183003 Q3 2022 ADIPIC ACID VAGINAL INSERT 57.00 mg MDE Replacement
183004 Q4 2022 ADIPIC ACID VAGINAL INSERT 171mg MDE Replacement
183005 Q3 2022 AMMONIUM ACETATE INTRAMUSCULAR INJECTION 0.80 %w/v MDE Replacement
183006 Q4 2022 AMMONIUM ACETATE INTRAMUSCULAR INJECTION 160mg MDE Replacement
183007 Q3 2022 AMMONIUM ACETATE INTRAVENOUS INJECTION 0.80 %w/v MDE Replacement
183008 Q4 2022 AMMONIUM ACETATE INTRAVENOUS INJECTION 160mg MDE Replacement
183009 Q3 2022 AMMONIUM SULFATE INTRAVENOUS INJECTABLE, LIPOSOMAL 0.20 %w/v MDE Replacement
183010 Q4 2022 AMMONIUM SULFATE INTRAVENOUS INJECTABLE, LIPOSOMAL 81mg MDE Replacement
183011 Q3 2022 ANHYDROUS CITRIC ACID INTRAVENOUS INJECTION, SOLUTION 0.53 %w/v MDE Replacement
183012 Q4 2022 ANHYDROUS CITRIC ACID INTRAVENOUS INJECTION, SOLUTION 540mg MDE Replacement
183013 Q3 2022 ANHYDROUS CITRIC ACID ORAL SUSPENSION 720.00 mg MDE Replacement
183014 Q4 2022 ANHYDROUS CITRIC ACID ORAL SUSPENSION 300mg MDE Replacement
183015 Q3 2022 ANHYDROUS CITRIC ACID ORAL SUSPENSION/ DROPS 2.50 mg/ 1.00 ml MDE Replacement
183016 Q4 2022 ANHYDROUS CITRIC ACID ORAL SUSPENSION/ DROPS 14mg MDE Replacement
183017 Q3 2022 ASCORBIC ACID TOPICAL GEL 0.30 %w/w MDE Replacement
183018 Q4 2022 ASCORBIC ACID TOPICAL GEL 3mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: October 1, 2022
Database Last Updated: October 19, 2022

Back to Top